Compare EPAC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | GLPG |
|---|---|---|
| Founded | 1910 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 1994 | N/A |
| Metric | EPAC | GLPG |
|---|---|---|
| Price | $33.46 | $27.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $48.00 | $36.50 |
| AVG Volume (30 Days) | ★ 345.8K | 263.2K |
| Earning Date | 03-25-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ 8.97 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $616,899,000.00 | N/A |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $5.56 | N/A |
| P/E Ratio | $49.54 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $32.35 | $26.62 |
| 52 Week High | $45.00 | $37.78 |
| Indicator | EPAC | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 36.53 |
| Support Level | $32.71 | N/A |
| Resistance Level | $36.56 | $34.04 |
| Average True Range (ATR) | 0.73 | 0.56 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 41.13 | 25.33 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.